Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10599045 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL6053356 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL6053361 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL1319561 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL5132709 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL5865848 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL9397393 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL9262998 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL777950 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRHTR6CA1CA2 | |
| SCHEMBL10607916 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRHTR6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483272-B | Novel method for asymmetric synthesis of (1S,2S) -2-fluorocyclopropanecarboxylic acid by catalysis of chiral rhodium catalyst | 广州康瑞泰药业有限公司 | 2022-09-27 | — | — | CN | claimed |
| US-10385000-B2 | Method for synthesizing 2-fluorocyclopropane carboxylic acid | CHEN-STONE (GUANGZHOU) CO., LTD. (CN) | 2019-08-20 | — | — | US | claimed |
| US-20180370893-A1 | NEW METHOD FOR SYNTHESIZING 2-FLUOROCYCLOPROPANE CARBOXYLIC ACID | CHEN-STONE (GUANGZHOU) CO., LTD. (CN) | 2018-12-27 | — | — | US | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-113493386-B | Novel high-selectivity asymmetric synthesis process of 2-fluorocyclopropylamine | 北京桦冠生物技术有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-110483272-B | Novel method for asymmetric synthesis of (1S,2S) -2-fluorocyclopropanecarboxylic acid by catalysis of chiral rhodium catalyst | 广州康瑞泰药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-110483272-B | Novel method for asymmetric synthesis of (1S,2S) -2-fluorocyclopropanecarboxylic acid by catalysis of chiral rhodium catalyst | 广州康瑞泰药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-114096546-A | Macrocyclic spirocyclic derivatives useful as MCL-1 inhibitors | 詹森药业有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113493386-A | Novel high-selectivity asymmetric synthesis process of 2-fluorocyclopropylamine | 北京桦冠生物技术有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20050182112-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| EP-1480975-A2 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072576-A2 | OXAZOLIDINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385000-B2 | Method for synthesizing 2-fluorocyclopropane carboxylic acid | FOSB, FDPS, PFAS | SMN1; SMN2 4347/4885TSHR 1676/4885HTR6 4346/4885 |
| US-20050182112-A1 | Chemical compounds | CYP8B1, H1-0, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 2342/4885TSHR 1794/4885HTR6 185/4885 |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | SMN1; SMN2 1289/4885TSHR 1608/4885HTR6 2018/4885 |
| US-20180370893-A1 | NEW METHOD FOR SYNTHESIZING 2-FLUOROCYCLOPROPANE CARBOXYLIC ACID | FOSB, PFAS, TST | SMN1; SMN2 4361/4885TSHR 1637/4885HTR6 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.